TIANXIN PHARMA(SH:603235) Zheng Quan Zhi Xing·2025-06-10 10:51Core Viewpoint - The legal opinion letter from Beijing Zhonglun (Shanghai) Law Firm confirms that Jiangxi Tianxin Pharmaceutical Co., Ltd.'s differentiated dividend distribution for the year 2024 complies with applicable laws and regulations, ensuring no harm to the interests of the company and its shareholders [10]. Group 1: Differentiated Dividend Distribution - The company plans to distribute a cash dividend of 0.68 RMB per share (including tax) to all shareholders, totaling approximately 295.92 million RMB based on the actual number of shares eligible for profit distribution [6]. - The total amount for cash dividends and share repurchase is approximately 355.92 million RMB, which accounts for 54.65% of the net profit attributable to shareholders for the year [6]. Group 2: Share Repurchase Plan - The company approved a share repurchase plan on January 22, 2024, with a total fund allocation between 60 million RMB and 120 million RMB, at a maximum price of 33.00 RMB per share, to be executed within 12 months [5]. Group 3: Legal Compliance and Verification - The law firm verified that all documents provided by the company are true, accurate, and complete, and that the company has obtained all necessary government approvals and licenses [2][3]. - The law firm emphasizes that it does not provide professional opinions on accounting, auditing, or evaluation matters, relying instead on documents from relevant intermediaries [4].